Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 7/20 | 0.39 |
| ▸ | KHK | P50053 | 6/20 | 0.37 |
| ▸ | PDE1A | P54750 | 3/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5884372 | 0.81 | PDE5A (0.42) | PDE5AKHKPDE1APDE1BPDE1C | |
| SCHEMBL5884120 | 0.80 | PDE5A (0.50) | PDE5AKHKPDE1APDE1BPDE1C | |
| SCHEMBL5884078 | 0.80 | KHK (0.35) | PDE5AKHK | |
| SCHEMBL5884034 | 0.77 | PDE5A (0.56) | PDE5AKHKPDE1APDE1BPDE1C | |
| SCHEMBL5883964 | 0.77 | PDE5A (0.46) | PDE5AKHKPDE1APDE1BPDE1C | |
| SCHEMBL5929371 | 0.77 | PDE5A (0.41) | PDE5AKHKPDE1APDE1BPDE1C | |
| SCHEMBL5929145 | 0.76 | PDE5A (0.43) | PDE5AKHKPDE1APDE1BPDE1C | |
| SCHEMBL5883634 | 0.75 | PDE5A (0.46) | PDE5AKHKPDE1APDE1BPDE1C | |
| SCHEMBL5883970 | 0.75 | PDE5A (0.48) | PDE5AKHKPDE1APDE1BPDE1C | |
| SCHEMBL5884327 | 0.75 | PDE5A (0.46) | PDE5AKHKPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087605-B2 | 5-Ethyl-imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| EP-1397363-B1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2004-12-16 | — | — | US | disclosed |
| EP-1397363-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | Bayer HealthCare AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098880-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | EPX, TPMT, IL5 | PDE5A 409/4885KHK 2954/4885PDE1A 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.